Carbopol 974

Carbopol 974 (specifically Carbopol 974P) is a high-purity, cross-linked polyacrylic acid polymer used as a pharmaceutical excipient, mucoadhesive agent, and viscosity enhancer. In the context of clinical research, such as the Phase 1 trial NCT00637962 sponsored by St George's, University of London, it has been formulated as a vaginal gel to serve as a placebo and delivery vehicle for active antigens like the HIV-1 vaccine candidate CN54gp140. The formulation utilizes the polymer's bioadhesive properties to prolong the residence time of the vaccine on the vaginal mucosa, thereby supporting mucosal immunization strategies for HIV prevention. Although it contains no active pharmaceutical ingredient, it is categorized as an intervention in clinical studies evaluating mucosal vaccines and is valued for its ability to form a stable gel matrix.

Brand names

Carbopol 974Carbopol974Carbopol-974Carbopol 974PCarbopol974PCarbopol-974P

Other names

Carbopol 974P gelCarbopol974P gelCarbopol-974P gelcarbomer 974Pcarbomer974Pcarbomer-974Ppolyacrylic acid polymer